Ascendis Pharma A/S (NASDAQ:ASND) Upgraded to “Hold” by BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a sell rating to a hold rating in a research note released on Thursday morning, BidAskClub reports.

Other equities analysts have also recently issued reports about the company. CSFB upped their price objective on Ascendis Pharma A/S from $149.00 to $154.00 and gave the stock an outperform rating in a report on Wednesday, May 20th. Credit Suisse Group raised their price objective on Ascendis Pharma A/S from $149.00 to $154.00 and gave the company an outperform rating in a report on Wednesday, May 20th. SVB Leerink raised their price objective on Ascendis Pharma A/S from $170.00 to $173.00 and gave the company an outperform rating in a report on Wednesday, May 20th. Oppenheimer decreased their price objective on Ascendis Pharma A/S from $219.00 to $208.00 and set an outperform rating on the stock in a report on Wednesday, May 20th. Finally, Wedbush initiated coverage on Ascendis Pharma A/S in a report on Friday, June 26th. They set a buy rating and a $188.00 price objective on the stock. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $168.17.

Shares of Ascendis Pharma A/S stock traded down $2.46 during trading on Thursday, hitting $140.50. The stock had a trading volume of 2,338 shares, compared to its average volume of 163,888. The firm has a market cap of $7.76 billion, a price-to-earnings ratio of -26.87 and a beta of 0.90. Ascendis Pharma A/S has a 12 month low of $90.06 and a 12 month high of $158.93. The business’s 50-day moving average is $143.13 and its 200 day moving average is $135.47. The company has a current ratio of 13.19, a quick ratio of 13.19 and a debt-to-equity ratio of 0.06.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Tuesday, May 19th. The biotechnology company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.43) by $0.11. Ascendis Pharma A/S had a negative net margin of 2,231.94% and a negative return on equity of 36.56%. The company had revenue of $2.45 million during the quarter, compared to analyst estimates of $2.66 million. As a group, equities analysts expect that Ascendis Pharma A/S will post -6.47 EPS for the current year.

Institutional investors have recently made changes to their positions in the business. Sowell Financial Services LLC purchased a new position in Ascendis Pharma A/S in the 1st quarter worth approximately $32,000. Oppenheimer Asset Management Inc. purchased a new position in Ascendis Pharma A/S in the 1st quarter worth approximately $49,000. Tower Research Capital LLC TRC purchased a new position in Ascendis Pharma A/S in the 1st quarter worth approximately $52,000. US Bancorp DE increased its stake in Ascendis Pharma A/S by 56.4% in the 1st quarter. US Bancorp DE now owns 602 shares of the biotechnology company’s stock worth $68,000 after purchasing an additional 217 shares during the period. Finally, Private Ocean LLC purchased a new position in Ascendis Pharma A/S in the 1st quarter worth approximately $108,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Further Reading: How to Invest in Stocks with Increasing Dividends

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply